| 國立成功大學 |
2023 |
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
|
Hartmaier, R.J.;Markovets, A.A.;Ahn, M.J.;Sequist, L.V.;Han, J.-Y.;Cho, B.C.;Yu, H.A.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.-S.;Su, W.-C.;Kowalski, D.M.;Orlov, S.;Ren, S.;Frewer, P.;Ou, X.;Cross, D.A.E.;Kurian, N.;Cantarini, M.;J�nne, P.A. |
| 國立成功大學 |
2023 |
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
|
Sequist, L.V.;Yang, J.C.-H.;Yamamoto, N.;O'Byrne, K.;Hirsh, V.;Mok, T.;Geater, S.L.;Orlov, S.;Tsai, C.-M.;Boyer, M.;Su, W.-C.;Bennouna, J.;Kato, T.;Gorbunova, V.;Lee, K.H.;Shah, R.;Massey, D.;Zazulina, V.;Shahidi, M.;Schuler, M. |
| 臺大學術典藏 |
2022-06-27T07:02:08Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; CHONG-JEN YU; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; Yang P.-C.; Miller V.A. |
| 臺大學術典藏 |
2022-06-27T07:01:36Z |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|
Yang J.C.-H.; Sequist L.V.; Geater S.L.; Tsai C.-M.; Mok T.S.K.; Schuler M.; Yamamoto N.; CHONG-JEN YU; Ou S.H.I.; Zhou C.; Massey D.; Zazulina V.; Wu Y.-L. |
| 臺大學術典藏 |
2021-04-23T05:56:31Z |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist L.V.;Han J.-Y.;Ahn M.-J.;Cho B.C.;Yu H.;Kim S.-W.;Chih-Hsin Yang;Lee J.S.;Su W.-C.;Kowalski D.;Orlov S.;Cantarini M.;Verheijen R.B.;Mellemgaard A.;Ottesen L.;Frewer P.;Ou X.;Oxnard G.; Sequist L.V.; Han J.-Y.; Ahn M.-J.; Cho B.C.; Yu H.; Kim S.-W.; CHIH-HSIN YANG; Lee J.S.; Su W.-C.; Kowalski D.; Orlov S.; Cantarini M.; Verheijen R.B.; Mellemgaard A.; Ottesen L.; Frewer P.; Ou X.; Oxnard G. |
| 臺大學術典藏 |
2021-04-23T05:56:29Z |
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
|
Tan D.S.-W.;Leighl N.B.;Riely G.J.;Chih-Hsin Yang;Sequist L.V.;Wolf J.;Seto T.;Felip E.;Aix S.P.;Jonnaert M.;Pan C.;Tan E.Y.;Ko J.;Moody S.E.;Kim D.-W.; Tan D.S.-W.; Leighl N.B.; Riely G.J.; CHIH-HSIN YANG; Sequist L.V.; Wolf J.; Seto T.; Felip E.; Aix S.P.; Jonnaert M.; Pan C.; Tan E.Y.; Ko J.; Moody S.E.; Kim D.-W. |
| 臺大學術典藏 |
2021-04-23T05:56:26Z |
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC
|
Awad M.M.;Gadgeel S.M.;Borghaei H.;Patnaik A.;Chih-Hsin Yang;Powell S.F.;Gentzler R.D.;Martins R.G.;Stevenson J.P.;Altan M.;Jalal S.I.;Panwalkar A.;Gubens M.;Sequist L.V.;Saraf S.;Zhao B.;Piperdi B.;Langer C.J.; Awad M.M.; Gadgeel S.M.; Borghaei H.; Patnaik A.; CHIH-HSIN YANG; Powell S.F.; Gentzler R.D.; Martins R.G.; Stevenson J.P.; Altan M.; Jalal S.I.; Panwalkar A.; Gubens M.; Sequist L.V.; Saraf S.; Zhao B.; Piperdi B.; Langer C.J. |
| 臺大學術典藏 |
2020-12-02T02:34:00Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; PAN-CHYR YANG; Miller V.A. |
| 臺大學術典藏 |
2020-08-13T06:33:49Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Miller V.A.; Yang P.-C.; Lorence R.M.; Cong X.J.; Shahidi M.; Dudek A.Z.; Sequist L.V.; Yang J.C.H.; JIN-YUAN SHIH; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:08Z |
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
|
Pao W.; Riely G; Ladanyi M; Zakowski M.F; Taron M; Rosell R; Pao W.;Riely G;Ladanyi M;Zakowski M.F;Taron M;Rosell R;Waltman B;Ji H;Chih-Hsin Yang;Chen H;Sequist L.V;Jackman D.M;Sima C.S;Girard N; Girard N; Sima C.S; Jackman D.M; Sequist L.V; Chen H; CHIH-HSIN YANG; Ji H; Waltman B |
